Ibodutant

Ibodutant
Systematic (IUPAC) name
	Nα-[(1-{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-N-{[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]methyl}-D-phenylalaninamide
Clinical data
Pregnancy cat.	?
Legal status	?
Routes	Oral
Identifiers
ATC code	None
PubChem	CID 11527495
ChemSpider	9702281
UNII	1H7RSQ28BJ
Synonyms	6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4- yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide
Chemical data
Formula	C37H48N4O4S
Mol. mass	644.866 g/mol
	SMILES CC1=CC2=C(C=C1)C=C(S2)C(=O)NC3(CCCC3)C(=O)NC(CC4=CC=CC=C4)C(=O)NCC5CCN(CC5)CC6CCOCC6;
	InChI InChI=1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1; Key:YQYSVMKCMIUCHY-WJOKGBTCSA-N ;
(what is this?) (verify);

Ibodutant is a candidate drug against irritable bowel syndrome, developed by The Menarini Group. As of May 2008^[update], it is undergoing a multicentre double blind dose finding study.

Method of action [edit]

Ibodutant selectively blocks the tachykinin receptor NK₂. Blockage is practically complete in nanomolar concentrations.

H. Spreitzer (May 26, 2008). "Neue Wirkstoffe - Ibodutant". Österreichische Apothekerzeitung (in German) (11/2008): 541.
S. Giuliani, M. Altamura, C. A. Maggi. "Ibodutant. Tachykinin NK₂ receptor antagonist, Treatment of irritable bowel syndrome.". Drugs of the Future 33 (2): 111–115.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.